Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
暂无分享,去创建一个
Richard A. Moore | Lisle E. Mose | David I Heiman | C. Sander | E. Mardis | L. Chin | G. Getz | M. Meyerson | L. Fulton | C. Perou | J. Weinstein | G. Mills | D. Wheeler | M. McLellan | Heather K. Schmidt | R. Verhaak | R. Beroukhim | Nicolas Stransky | P. Laird | D. Weisenberger | S. Baylin | D. Hayes | K. Hoadley | S. Balu | T. Shelton | S. Morris | M. Ferguson | J. Schein | M. Marra | N. Thiessen | Steven J. M. Jones | R. Holt | A. G. Robertson | Angela Tam | P. Mieczkowski | J. Parker | Jaegil Kim | G. Saksena | Douglas Voet | M. Noble | Pei Lin | David I. Heiman | J. Kocher | Juok Cho | A. Mungall | K. Mungall | C. Fronick | Adrian Ally | M. Balasundaram | Noreen Dhalla | Michael Mayo | R. Akbani | J. Gastier-Foster | T. Lichtenberg | L. Wise | John A. Demchok | Margi Sheth | H. Sofia | Liming Yang | S. Schumacher | W. Rathmell | A. Cherniack | Payal Sipahimalani | R. Carlsen | J. Auman | Donghui Tan | Corbin D. Jones | S. Jefferys | T. Bodenheimer | A. Hoyle | J. Simons | Phillip H. Lai | M. Bootwalla | Hailei Zhang | N. Gehlenborg | S. Frazer | Yiling Lu | R. Shen | C. Shelton | J. Gardner | D. Mallery | J. Paulauskis | Erin E. Curley | L. Thorne | L. Boice | T. Pihl | Zhining Wang | R. Tarnuzzer | J. Zhang | Jia Liu | E. Reznik | T. Hinoue | S. Meng | T. Skelly | A. Zhu | F. Farshidfar | R. Bowlby | C. Pedamallu | A. I. Ojesina | Ina Felau | C. Hutter | J. Zenklusen | Sudha Chudamani | Laxmi Lolla | R. Naresh | Yunhu Wan | Ye Wu | T. DeFreitas | S. Meier | A. Hegde | Denise Brooks | K. Kasaian | Yussanne Ma | S. Sadeghi | Tina Wong | C. Cibulskis | J. Shih | D. J. Van Den Berg | Amy H. Perou | J. Roach | Matthew G. Soloway | Umadevi Veluvolu | K. Covington | E. Shinbrot | Liu Xi | J. Hess | M. Cordes | D. Crain | M. Gerken | N. Ramirez | E. Zmuda | A. D. De Rose | F. Giuliante | K. Evason | M. Borad | V. Chandan | N. Giama | C. Moser | L. Roberts | M. Torbenson | Ju Dong Yang | G. Genovese | L. Kwong | N. Bardeesy | D. Kleiner | Siyuan Zheng | V. Deshpande | M. Gingras | Arshi Arora | Bradley A. Murray | Amie Radenbaugh | O. Bathe | Andrea E Holbrook | Mario Berrios | E. Gibb | S. Rhie | A. Franchitto | G. Carpino | E. Gaudio | H. Stoppler | Yulia Newton | J. Roszik | G. Grazi | D. Alvaro | M. Bragazzi | V. Cardinale | Chia-Chin Wu | J. Andersen | T. Mounajjed | Yan Shi | T. Patel | R. Chaiteerakij | Gina Choe | André L. Carvalho | R. Shroff | Qiang Sun | A. McRee | Elizabeth L. Appelbaum | Loretta K. Allotey | W. Foo | M. Matsushita | E. Chuah | K. Leraas | Josh M Stuart | Li Ding | Daniel R. O’Brien | Qiang Sun | R. Kelley | Mike S. Lawrence | S. Gabriel | Mei Huang | Jay Bowen | R. Penny | Richard A. Gibbs | J. Yang | J. D. Yang | Christopher A. Miller | N. Stransky | Robert S. Fulton | Wenbin Liu | R. Wilson | C. A. Miller | R. Shen | J. Parker | A. G. Robertson | Tara J. Skelly
[1] Gad Getz,et al. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. , 2017, Cancer discovery.
[2] Andrew X. Zhu,et al. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise , 2016, The oncologist.
[3] Eve Shinbrot,et al. Mutation signatures reveal biological processes in human cancer , 2016, bioRxiv.
[4] M. Fassan,et al. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients , 2016, Annals of Surgical Oncology.
[5] A. Iafrate,et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. , 2015, Cancer Cell.
[6] E. Maher,et al. Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas , 2015 .
[7] Thomas P. Howard,et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.
[8] S. Thorgeirsson,et al. Functional and genetic deconstruction of the cellular origin in liver cancer , 2015, Nature Reviews Cancer.
[9] T. Graeber,et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. , 2015, Cell metabolism.
[10] S. Armstrong,et al. Loss of BAP1 function leads to EZH2-dependent transformation , 2015, Nature Medicine.
[11] Hiromi Nakamura,et al. Genomic spectra of biliary tract cancer , 2015, Nature Genetics.
[12] Christian M. Metallo,et al. Metabolic consequences of oncogenic IDH mutations. , 2015, Pharmacology & therapeutics.
[13] N. Bardeesy,et al. Biliary Tract Cancers: Finding Better Ways to Lump and Split. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] V. Deshpande,et al. Difficult Diagnostic Problems in Pancreatobiliary Neoplasia. , 2015, Archives of pathology & laboratory medicine.
[15] Martin L. Miller,et al. Mitochondrial DNA copy number variation across human cancers , 2015, bioRxiv.
[16] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[17] E. Cuyás,et al. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype , 2015, Oncotarget.
[18] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[19] E. Schadt,et al. Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma , 2015, Nature Communications.
[20] G. Mills,et al. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications , 2014, PloS one.
[21] Nansheng Chen,et al. Mutational landscape of intrahepatic cholangiocarcinoma , 2014, Nature Communications.
[22] Lawrence A. Donehower,et al. The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.
[23] K. Ross,et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.
[24] Benjamin J. Raphael,et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.
[25] Y. Jeng,et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features , 2014, Modern Pathology.
[26] Christian M. Metallo,et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. , 2014, Cancer research.
[27] Y. Totoki,et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.
[28] David M. Jones,et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. , 2014, The oncologist.
[29] Eric W. Klee,et al. Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma , 2014, PLoS genetics.
[30] Swe Swe Myint,et al. Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.
[31] T. Pawlik,et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.
[32] S. Thorgeirsson,et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. , 2013, Gastroenterology.
[33] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[34] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[35] Bárbara Martínez-Pastor,et al. A tale of metabolites: the cross-talk between chromatin and energy metabolism. , 2013, Cancer discovery.
[36] W. Kaelin,et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.
[37] Derek Y. Chiang,et al. Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas , 2012, Oncogene.
[38] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[39] Hyun Goo Woo,et al. Transcriptomic profiling reveals hepatic stem‐like gene signatures and interplay of miR‐200c and epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma , 2012, Hepatology.
[40] Masakazu Yamamoto,et al. Intrahepatic Cholangiocarcinoma With Predominant “Ductal Plate Malformation” Pattern: A New Subtype , 2012, The American journal of surgical pathology.
[41] Sayaka Sekiya,et al. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. , 2012, The Journal of clinical investigation.
[42] Jesse S. Voss,et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. , 2012, Human pathology.
[43] G. Gores,et al. Cholangiocarcinomas can originate from hepatocytes in mice. , 2012, The Journal of clinical investigation.
[44] W. Palmer,et al. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.
[45] Young Bae Kim,et al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma‐like gene expression trait and epithelial‐mesenchymal transition , 2012, Hepatology.
[46] Bin Tean Teh,et al. Exome sequencing of liver fluke–associated cholangiocarcinoma , 2012, Nature Genetics.
[47] Itzhak Avital,et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.
[48] C. Rock,et al. Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation* , 2012, The Journal of Biological Chemistry.
[49] Jeffrey W. Clark,et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.
[50] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[51] R. Jove,et al. miR‐194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice , 2010, Hepatology.
[52] Jung-Hwan Yoon,et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. , 2010, Cancer research.
[53] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[54] R. Reznek,et al. Cancer of unknown primary site. , 2008, Clinical medicine.